Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Lyric Pharmaceuticals

Request full access

Clinical stage company developing novel gastrointestinal therapeutics for unmet medical needs in the hospital setting

San Francisco, United StatesFounded 2013Biotech & Life Sciences

About Lyric Pharmaceuticals

Lyric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company established in 2013, with a focus on developing treatments for gastrointestinal (GI) indications, particularly for unmet needs in the hospital and intensive care unit (ICU) settings. The company was co-founded by biopharma veterans Dr. David Wurtman, who serves as President and CEO, and Dr. M. Scott Harris, the Chief Medical Officer. The founding journey began when Dr. Harris, with prior experience as CMO at Avaxia Biologics, identified a key opportunity in the GI space and approached Dr. Wurtman. Together, they targeted a specific disease area and in-licensed their initial development candidate in September 2014.

The company's business model is centered on the clinical development and eventual commercialization of novel therapeutics. Its primary clients are critically ill patients within hospital ICUs. Lyric operates by raising capital from venture partners to fund multi-phase clinical trials required for drug approval. The company secured initial seed funding of $825,000 in 2014, led by RiverVest Venture Partners. This was followed by a significant Series A financing round, ultimately totaling $27.6 million by 2017, with lead investors including RiverVest Venture Partners, Sante Ventures, and Third Point Ventures.

Lyric's lead product candidate is LP-101, also known as ulimorelin, an intravenous ghrelin agonist. Ghrelin is often called the "feeding hormone," and agonists like ulimorelin are designed to offer both gastrointestinal pro-motility and pro-metabolic effects. LP-101 was specifically developed to treat Enteral Feeding Intolerance (EFI), a common and acute disorder of gastric motor function in critically ill, tube-fed patients that is associated with significant morbidity and mortality. In January 2018, the U.S. FDA granted Fast Track designation for the investigation of ulimorelin for EFI, highlighting the significant unmet medical need as no drug is currently approved for this condition. By March 2018, the company had completed enrollment for its Phase 2 PROMOTE study, an international, multicenter trial for LP-101. Prior to this, the drug had been administered to over 1,000 patients and volunteers with a favorable safety profile. However, as of early 2021, reports indicated that development for nutrition disorders had not progressed beyond Phase 2, and development for other conditions like gastroparesis and cachexia was discontinued. Some data sources now classify the company as deadpooled.

Source: Dealroom company data

At a glance

Status
Closed
Founded
2013
Headquarters
San Francisco, United States
Open positions
None listed
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Feb 2015 $20M $82M RiverVest Venture Partners · Aperture Venture Partners · Third Point Ventures · Sante Ventures —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Lyric Pharmaceuticals website traffic

Latest recorded traffic for Lyric Pharmaceuticals is 0 monthly website visits, down 100% over the last three months.

Latest monthly visits0 3-month web change-100%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Lyric Pharmaceuticals in the San Francisco ecosystem

Live from Dealroom

The Lyric Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • RiverVest Venture Partners
  • Third Point Ventures
  • Aperture Venture Partners
  • Sante Ventures
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Francisco HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Lyric Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Lyric Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.